Last Updated: June 24, 2026

SUBVENITE Drug Patent Profile

Name: SUBVENITE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Subvenite patents expire, and what generic alternatives are available?

Subvenite is a drug marketed by Owp Pharms and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in SUBVENITE is lamotrigine. There are thirty-two drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Subvenite

A generic version of SUBVENITE was approved as lamotrigine by DR REDDYS LABS LTD on January 22^nd, 2009.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for SUBVENITE?
What are the global sales for SUBVENITE?
What is Average Wholesale Price for SUBVENITE?

Summary for SUBVENITE

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	5,799
Drug Prices:	Drug price information for SUBVENITE
What excipients (inactive ingredients) are in SUBVENITE?	SUBVENITE excipients list
DailyMed Link:	SUBVENITE at DailyMed

Drug patent expirations by year for SUBVENITE

Pharmacology for SUBVENITE

Drug Class	Anti-epileptic Agent Mood Stabilizer
Mechanism of Action	Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for SUBVENITE

SUBVENITE is protected by six US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Owp Pharms	SUBVENITE	lamotrigine	SUSPENSION;ORAL	218879-001	Sep 16, 2025		RX	Yes	Yes	11,596,634	⤷ Start Trial				⤷ Start Trial
Owp Pharms	SUBVENITE	lamotrigine	SUSPENSION;ORAL	218879-001	Sep 16, 2025		RX	Yes	Yes	11,612,566	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.